AXIOMPHARMACEUTICALS
AXIOMPHARMACEUTICALS
WhatsAppAccount
Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Tissue repair & recovery

Thymosin Alpha 1 (Ta1)

Synthetic Thymic Hormone · Immune System Modulator

Research use onlyGBP reference pricing where listedUK dispatch on catalogue items
Database

Overview

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

Activates TLR pathways, T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

FDA orphan designation for DiGeorge syndrome; restores T-cell function.

Improved antibody responses in elderly and hemodialysis patients (H1N1, COVID-19).

Restores CD4+ counts and reduces opportunistic infections.

Mechanism

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

Activates TLR pathways, T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

FDA orphan designation for DiGeorge syndrome; restores T-cell function.

Research areas

  • Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.
  • Activates TLR pathways, T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.
  • FDA orphan designation for DiGeorge syndrome; restores T-cell function.
  • Improved antibody responses in elderly and hemodialysis patients (H1N1, COVID-19).
  • Restores CD4+ counts and reduces opportunistic infections.

Research notes

  • Mild injection site reactions (<10% incidence)
  • Generally well-tolerated with safety record
  • Signs of graft rejection in transplant recipients
  • Persistent injection site reactions or infection signs
  • Unusual immune system hyperactivity

Pharmacokinetics

  • Activates TLR pathways, T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

References

Questions

Can Thymosin Alpha-1 be combined with coronavirus vaccines to boost protection?

Yes, Thymosin Alpha-1 antibody responses to vaccines in elderly and immunocompromised patients. Clinical trials show improved vaccine immunogenicity with co-administration. This is particularly relevant for high-risk groups seeking vaccine protection.

Does Thymosin Alpha-1 actually work for COVID-19 or just reduce symptoms?

A clinical trial showed Thymosin Alpha-1 significantly reduced mortality in severe COVID-19 (11.11% vs 30% untreated, P=0.044) by restoring CD4+ and CD8+ T-cell numbers and reversing T-cell exhaustion. It works by immune restoration rather than direct antiviral activity.

Why is Thymosin Alpha-1 less popular than other immune peptides if it's studied so extensively?

Despite 11,000+ patients in 30+ trials with excellent safety (<1% serious adverse events), Thymosin Alpha-1 has limited commercial availability. It's not FDA-approved for most indications (only orphan status for DiGeorge syndrome), making prescription access difficult outside research settings or specific countries.